OLAPARIB, OLAPARIB, CARBOPLATIN, BEVACIZUMAB, PACLITAXEL, BEVACIZUMAB clinical trials

A multi-centre, four-arm, randomised, double-blind study assessing the dose equivalence of bevacizumab in first-line therapy for ovarian cancer

This study is testing different doses of a drug called bevacizumab, alongside other treatments, for women with ovarian, fallopian tube, or peritoneal cancer. We want to see how well these treatments shrink tumours and if they help people live longer without their cancer getting worse.